Загрузка...
Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival? A Comparative Effectiveness Study in a Population-Based Sample
PURPOSE: Epidermal growth factor receptor (EGFR) inhibitors are approved for treating metastatic colorectal cancer (CRC); KRAS mutation testing is recommended prior to treatment. We conducted a non-inferiority analysis to examine whether KRAS testing has impacted survival in CRC patients. PATIENTS A...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Public Library of Science
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4006772/ https://ncbi.nlm.nih.gov/pubmed/24788807 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0094977 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|